// STATE LEGISLATION TRACKER

Illinois HB 5517: HEALTH CARE COSTS ACT

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed

State: Illinois
Bill: HB 5517
Filed: 2024-02-09
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

Illinois HB5517 was a broad health care cost bill focused on drug discount cards, drug price transparency, pharma sales rep registration, PBM review, facility fees, Medicare Advantage practices, and certificate-of-need notices. It does not appear to regulate compounded peptides, 503A/503B pharmacies, off-label prescribing, telehealth, NP or naturopath scope, controlled substances, or prescription monitoring.

Key Points

No apparent new restriction on compounded peptides or 503A/503B pharmacies
No apparent change to off-label prescribing or peptide telehealth access
Drug discount card could help standard prescriptions, not compounded or gray-market products
High-cost drug reporting could indirectly include FDA-approved peptide drugs if selected
Facility fee rules affect clinic billing more than peptide access

What to Watch For

Note The bill failed when the 103rd General Assembly ended, so it has no current legal effect.

✓

Opportunity If refiled, the drug discount card could modestly improve access to covered prescription drugs.

Note Future versions could matter more if they add compounding, PBM, or prescriber-scope language.

Where the Bill Stands

HB5517 ended with Session Sine Die on January 7, 2025, meaning it failed without becoming law.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws